Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers

Gschwantler‐Kaulich, Daphne; Weingartshofer, Sigrid; Rappaport-Fürhauser, Christine; Zeillinger, Robert; Pils, Dietmar; Muhr, Daniela; Braicu, Elena I.; Kastner, Marie-Therese; Tan, Yen Y.; Semmler, Lorenz; Sehouli, Jalid; Singer, Christian F.

doi:10.1371/journal.pone.0196142

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, there have been diverse proteomic studies associated with OC that have utilized liquid chromatography-mass spectrometry (LC-MS). Most of these prior investigations have mainly focused on new biomarker identification among differentially abundant proteins in blood-derived specimens [ 18 , 19 , 20 , 21 ] or in tumor tissues [ 22 , 23 ]. Previous studies on the integration of genes and proteins have also been conducted in OC [ 24 , 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers

Ahn

et al. 2021

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most lethal gynecologic malignancy and in-time diagnosis is limited because of the absence of effective biomarkers. Germline BRCA1/2 genetic alterations are risk factors for hereditary OC; risk-reducing salpingo-oophorectomy (RRSO) is pursued for disease prevention. However, not all healthy carriers develop the disease. Therefore, identifying predictive markers in the BRCA1/2 carrier population could help improve the identification of candidates for preventive RRSO. In this study, plasma samples from 20 OC patients (10 patients with BRCA1/2 wild type (wt) and 10 with the BRCA1/2 variant (var)) and 20 normal subjects (10 subjects with BRCA1/2wt and 10 with BRCA1/2var) were analyzed for potential biomarkers of hereditary OC. We applied a bottom-up proteomics approach, using nano-flow LC-MS to analyze depleted plasma proteome quantitatively, and potential plasma protein markers specific to the BRCA1/2 variant were identified from a comparative statistical analysis of the four groups. We obtained 1505 protein candidates from the 40 subjects, and SPARC and THBS1 were verified by enzyme-linked immunosorbent assay. Plasma SPARC and THBS1 concentrations in healthy BRCA1/2 carriers were found to be lower than in OC patients with BRCA1/2var. If plasma SPARC concentrations increase over 337.35 ng/ml or plasma THBS1 concentrations increase over 65.28 mg/ml in a healthy BRCA1/2 carrier, oophorectomy may be suggested.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers

Ahn

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers

Cited by 1 publication

References 1 publication

Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers

Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers

Contact Info

Product

Resources

About